Author Correction: Biosurfactant Production by Lactic Acid Bacterium Pediococcus dextrinicus SHU1593 Grown on Different Carbon Sources: Strain Screening Followed by Product Characterization

Ghasemi, Abouzar; Moosavi‐Nasab, Marzieh; Setoodeh, Payam; Mesbahi, Gholamreza; Yousefi, Gholamhossein

doi:10.1038/s41598-020-58139-8

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are amphiphilic compounds produced by microorganisms, anchored on the surface, or secreted to the outside, with outstanding surface and emulsifying properties ( Santos et al, 2016 ). BS are produced by LAB strains including vaginal Lactobacillus species and have anti-adhesive abilities against pathogens with no exception to Candida species ( Sarwar et al, 2018 ; Ghasemi et al, 2020 ). Overall, BS isolated LAB strains in human urogenital and gastrointestinal tracts, have proven to be highly effective in eliminating pathogenic bacteria and fungi adhering on various surfaces including medical implants ( Satpute et al, 2016 ; Merghni et al, 2017 ; Yan X. et al, 2019 ).…”

Section: Role Of Biotics In Preventing Biofilms Prevalence In Vulvova...mentioning

confidence: 99%

The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections

et al. 2022

View full text Add to dashboard Cite

“Unity in strength” is a notion that can be exploited to characterize biofilms as they bestow microbes with protection to live freely, escalate their virulence, confer high resistance to therapeutic agents, and provide active grounds for the production of biofilms after dispersal. Naturally, fungal biofilms are inherently resistant to many conventional antifungals, possibly owing to virulence factors as their ammunitions that persistently express amid planktonic transition to matured biofilm state. These ammunitions include the ability to form polymicrobial biofilms, emergence of persister cells post-antifungal treatment and acquisition of resistance genes. One of the major disorders affecting vaginal health is vulvovaginal candidiasis (VVC) and its reoccurrence is termed recurrent VVC (RVVC). It is caused by the Candida species which include Candida albicans and Candida glabrata. The aforementioned Candida species, notably C. albicans is a biofilm producing pathogen and habitually forms part of the vaginal microbiota of healthy women. Latest research has implicated the role of fungal biofilms in VVC, particularly in the setting of treatment failure and RVVC. Consequently, a plethora of studies have advocated the utilization of probiotics in addressing these infections. Specifically, the excreted or released compounds of probiotics which are also known as postbiotics are being actively researched with vast potential to be used as therapeutic options for the treatment and prevention of VVC and RVVC. These potential sources of postbiotics are harnessed due to their proven antifungal and antibiofilm. Hence, this review discusses the role of Candida biofilm formation in VVC and RVVC. In addition, we discuss the application of pro-, pre-, post-, and synbiotics either individually or in combined regimen to counteract the abovementioned problems. A clear understanding of the role of biofilms in VVC and RVVC will provide proper footing for further research in devising novel remedies for prevention and treatment of vaginal fungal infections.

show abstract